Scarica l'app Stockscreener
27.47
0.07%
0.02
Dopo l'orario di chiusura:
27.47
Agios Pharmaceuticals Inc Borsa (AGIO) Ultime notizie
JP Morgan Raises Price Target for Agios Pharmaceuticals (AGIO) t - GuruFocus
Agios Pharmaceuticals, Inc. Being Investigated on Behalf of Agios Pharmaceuticals, Inc. Investors. Contact Levi & Korsinsky For Details - ACCESS Newswire
Agios Pharmaceuticals, Inc. (AGIO): Investor Outlook Highlights A Potential 33% Upside - DirectorsTalk Interviews
Agios to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 - The Manila Times
Insider Selling: Agios Pharmaceuticals (NASDAQ:AGIO) Insider Sells 2,932 Shares of Stock - MarketBeat
Agios Pharmaceuticals (NASDAQ:AGIO) CFO Sells $79,427.88 in Stock - MarketBeat
Agios Pharmaceuticals (NASDAQ:AGIO) CEO Brian Goff Sells 18,703 Shares - MarketBeat
Agios pharma chief legal officer Burns sells $79k in stock - Investing.com Canada
Agios pharma chief medical officer Gheuens sells $79k in stock - Investing.com Canada
Agios Pharmaceuticals CEO Goff sells $506,663 in stock By Investing.com - Investing.com Australia
Agios Pharmaceuticals CEO Goff sells $506,663 in stock - Investing.com
Jones Cecilia, Agios Pharmaceuticals CFO, sells $79k in stock By Investing.com - Investing.com UK
Agios pharma CCO Milanova sells $79k in stock after option exercise - Investing.com UK
Agios Pharma shares jump 16% as US FDA expands approval for blood disorder drug - MSN
Momentum Indicator Shows Bearish Divergence in Sylvan Plyboard India LimitedRisk-Reward Ratio Analysis & Stay Ahead With Daily Market Discussions - earlytimes.in
How Agios Pharmaceuticals Inc. stock valuations compare to rivalsStock Correlation Metrics & Free Superior Profit Margins - bollywoodhelpline.com
Agios Pharma jumps 15% as FDA expands use of anaemia drug mitapivat - MSN
Geopolitics Watch: Is Agios Pharmaceuticals Inc 8AP stock attractive post correctionLayoff News & Low Risk Entry Point Tips - moha.gov.vn
FDA approves Agios’ AQVESME (mitapivat) for the treatment of anemia in adults - MSN
Agios Pharmaceuticals (NASDAQ:AGIO) Shares Down 5.3%Should You Sell? - MarketBeat
Capital One Financial To Rally More Than 24%? Here Are Top Analyst Forecasts For Friday - Benzinga
AGIO: Analyst Andrew Berens Raises Agios Pharmaceuticals Price T - GuruFocus
Agios Pharmaceuticals (AGIO) Surges 18.6%: Is This an Indication of Further Gains? - Yahoo Finance
BofA Securities raises Agios Pharma stock price target on FDA approval - Investing.com India
Agios (AGIO) Gets 18.6% Boost from Aqvesme OK - Finviz
B of A Securities Maintains Agios Pharmaceuticals (AGIO) Buy Recommendation - MSN
Agios Pharmaceuticals price target raised to $34 from $32 at BofA - Yahoo Finance
Agios Stock (+19%): AQVESME Thalassemia Approval Ignites Re-Rate - Trefis
Agios Pharma shares jump as US FDA expands approval for blood disorder drug - wibqam.com
Why Agios Pharmaceuticals (AGIO) Is Up 14.6% After First-in-Class Thalassemia Drug AQVESME Wins FDA Approval - Sahm
Agios Pharma stock price target raised to $62 from $48 at H.C. Wainwright - Investing.com India
Truist Financial Forecasts Strong Price Appreciation for Agios Pharmaceuticals (NASDAQ:AGIO) Stock - MarketBeat
Agios Pharma Stock: A Buy After FDA Approves Aqvesme (NASDAQ:AGIO) - Seeking Alpha
Here's Why Shares in Agios Pharmaceuticals Popped Today - AOL.com
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Here's Why Shares in Agios Pharmaceuticals Popped Today - The Motley Fool
Agios Pharmaceuticals, Inc. (AGIO) Discusses FDA Approval of AQVESME for Anemia in Alpha and Beta ThalassemiaSlideshow (NASDAQ:AGIO) 2025-12-24 - Seeking Alpha
First oral anemia treatment across thalassaemia types approved in USA - The Pharma Letter
AGIO's Mitapivat Gets FDA Nod for Thalassemia Indication with REMS in Label - Eastern Progress
Agios Pharma shares jump as US FDA expands approval for its blood disorder drug - Yahoo Finance
Agios Pharmaceuticals (NASDAQ:AGIO) Shares Gap Up on Analyst Upgrade - MarketBeat
The $1.7 Billion Pivot: Agios Pharmaceuticals (AGIO) and the New Frontier of Oral Thalassemia Therapy - FinancialContent
AGIO (Agios Pharmaceuticals) EV-to-OCF : -1.89 (As of Dec. 24, 2025) - GuruFocus
Agios (AGIO) Surges 12% Following FDA Approval of New Thalassemi - GuruFocus
Agios Shares Rise After FDA Approves Aqvesme to Treat Anemia in Thalassemia Patients - marketscreener.com
Why Did AGIO Stock Surge 14% Today? - Stocktwits
Agios Pharmaceuticals stock soars after FDA approves AQVESME for thalassemia - Investing.com Canada
Transcript : Agios Pharmaceuticals, Inc.Special Call - marketscreener.com
2.52%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):